Trial Profile
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Aug 2016 Status changed from active, no longer recruiting to completed.
- 11 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Nov 2016, as reported by ClinicalTrials.gov.
- 04 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov record.